Showing results (261-270 of 544) with videos related to

Sort By:
Pageof 55
Vaccine: X|December 12, 2022
Humoral and T-cell mediated response after administration of mRNA vaccine BNT162b2 in frail populationsRoberta Campagna, Laura Mazzuti, Giuliana Guerrizio, et al.
Vaccine: X|November 22, 2022
Healthcare professionals' views on access to vaccines in Nigeria: A cross sectional studyObi Peter Adigwe, Davidson Oturu, Godspower Onavbavba
Vaccine: X|March 28, 2020
New analytic approaches for analyzing and presenting polio surveillance data to supplement standard performance indicatorsKristin VanderEnde, Arend Voorman, Sara Khan, et al.
Vaccine: X|November 21, 2022
COVID-19 site readiness initiative: Building clinical trial capacity for vaccine efficacy trials in Latin America in response to the pandemicSue Ann Costa Clemens, Ana Keiko Sekine, Fernanda Tovar-Moll, et al.
Vaccine: X|November 21, 2022
Key lessons learned from the immunization supply chain of Malawi, an African country using EVM2.0Ghanshyam Sethy, Mike Nenani Chisema, Lokesh Sharma, et al.
Vaccine: X|June 13, 2022
Signaling differences in peripheral blood mononuclear cells of high and low vaccine responders prior to, and following, vaccination in pigletsSean Lipsit, Antonio Facciuolo, Erin Scruten, et al.
Vaccine: X|June 13, 2022
SARS-CoV-2 antibody response after BNT162b2 mRNA vaccine in healthcare workers: Nine-month of follow-upFranco Mastroianni, Pietro Guida, Grazia Bellanova, et al.
Vaccine: X|June 20, 2022
COVID-19 vaccine hesitancy and influential factors among Thai parents and guardians to vaccinate their childrenAmornphat Kitro, Wachiranun Sirikul, Ekkamon Dilokkhamaruk, et al.
Vaccine: X|February 4, 2022
Human papillomavirus (HPV) infection and vaccination: A cross-sectional study of college students' knowledge, awareness, and attitudes in Villanova, PAJennifer A Goldfarb, Joseph D Comber
Vaccine: X|July 28, 2022
Antibody persistence following administration of a hexavalent DTwP-IPV-HB-PRP∼T vaccine versus separate DTwP-HB-PRP∼T and IPV vaccines at 12-24 months of age and safety and immunogenicity of a booster dose of DTwP-IPV-HB-PRP∼T in healthy infants in IndiaS Mangarule, S Palkar, M Mitra, et al.
Pageof 55